In Brief: Zeneca Diprivan
Executive Summary
Zeneca Diprivan: Patent valid until 2015 is granted for reformulation of the I.V. sedative hypnotic to add .005% disodium edetate to retard growth of microorganisms that could result from touch contamination. The patent for propofol without EDTA expired in November 1996. Zeneca received FDA approval to market the EDTA formulation on June 11, 1996 and was granted a three year exclusivity extension in March ("The Pink Sheet" March 24, 1997, T&G-3)...